Current mpox outbreak underscores gaps in access to medical countermeasures to help mitigate the severity of future outbreaks CAMBRIDGE, Mass. , Oct. 9, 2024 /PRNewswire/ -- Today, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead of future pandemics, released its Antiviral Clinical and Preclinical Development Landscape .
In this third edition report, the Alliance adds a list of preclinical antiviral compounds to its ongoing analysis of clinical antiviral compounds in development that target the 13 viral families identified 1 as having potential to result in a pandemic which now includes mpox. INTREPID's analysis shows that the majority of the 64 distinct direct-acting antiviral compounds in clinical phase studies target coronaviruses (SARS-CoV-2) and orthomyxoviruses (Influenza). Similarly, of the 96 distinct preclinical direct-acting antiviral compounds spanning the different stages of preclinical development, the majority target SARS-CoV-2 (COVID-19).
Non-COVID-19 preclinical compounds under study are primarily targeting Influenza. Further analysis reveals that there is no preclinical development activity found for 3 of the 13 viral families ( Nairoviridae , Peribunyaviridae , and Picornaviridae ), and no clinical development activity was found in 4 of the 13 viral families ( Hantaviridae , Peribunyaviridae , Paramyxoviridae , and Togaviridae ). These key findings in .
